Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Clinical trial NCT02120456 · COMPLETED
Trial details
- NCT number
- NCT02120456
- Sponsor
- LEO Pharma
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2015-05-01
- Enrollment
- 224
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.